Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway

AIM: Although EGFR tyrosine kinase inhibitors (TKIs) have shown dramatic effects against sensitizing EGFR mutations in non-small cell lung cancer (NSCLC), ~20%–30% of NSCLC patients with EGFR-sensitive mutation exhibit intrinsic resistance to EGFR-TKIs. The purpose of the current study was to invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yong-hong, Jiao, Lin, Lin, Cai-yu, Lu, Cong-hua, Li, Li, Chen, Heng-yi, Wang, Yu-bo, He, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6108345/
https://www.ncbi.nlm.nih.gov/pubmed/30154647
http://dx.doi.org/10.2147/BTT.S166867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6108345/
https://www.ncbi.nlm.nih.gov/pubmed/30154647
http://dx.doi.org/10.2147/BTT.S166867

Ejemplares similares